NEWS
- FDA Approves Palopegteriparatide for Hypoparathyroidism
- Radionuclide Drug Conjugates (RDCs): Current Status
- ADC in Combination with PD-1: Approvals and Clinical Trials
- ROR1 ADCs in Clinical Trials: MK-2140, NBE-002 & CS5001
- Trophoblast Glycoprotein (TPGB/5T4): A New Target For ADC Drugs
- Summary of ADC Targets For Solid Tumors & Hematological Tumors
- Advances in TROP-2 Directed ADCs
- Development of PD-L1 Antibody Drug Conjugates (ADC)
- Bispecific Antibody Drug Conjugates (ADCs): Emerging Trends
- Maytansinoids as Payloads of ADCs: DM1, DM4